Skip to content
DraconiticResearch
Search Sources API
190,860 studies31 sourcesUpdated 34 min ago
Peer-reviewedCC BY 4.0Journal of Clinical Medicine

Comparative Effects of Myo-Inositol, Metformin, Berberine, and Combination Therapy on Metabolic, Anthropometric and Hormonal Parameters in Women with Polycystic Ovary Syndrome: A 6-Month Observational Cohort Study

  • Vesselina Yanachkova1,2
  • Angel Yordanov3
  • Antonia Yaneva4
  • Hristina Lebanova5
  • Svetoslav Stoev5
5 affiliations
  1. 1Research Institute, Medical University-Pleven, 5800 Pleven, Bulgaria
  2. 2Department of Endocrinology, Specialized Hospital for Active Treatment of Obstetrics and Gynecology “Dr. Shterev”, 1330 Sofia, Bulgaria
  3. 3Department of Gynecologic Oncology, Medical University-Pleven, 5800 Pleven, Bulgaria
  4. 4Department of Medical Informatics, Biostatistics and E-learning, Faculty of Public Health, Medical University-Plovdiv, 4002 Plovdiv, Bulgaria
  5. 5Department of Pharmaceutical Sciences and Social Pharmacy, Faculty of Pharmacy, Medical University-Pleven, 5800 Pleven, Bulgaria
Read full textPDFDOICite

Abstract

Background: Polycystic ovary syndrome (PCOS) is the most prevalent endocrine condition among women of reproductive age. It is marked by metabolic and reproductive irregularities and is often linked to insulin resistance, dyslipidemia, and obesity. Diverse methods of treatment are employed to enhance metabolic and hormonal parameters, including inositol-based supplements, metformin, and novel compounds such as berberine. Objective: To describe changes observed over six months in anthropometric, metabolic, lipid, and hormonal metrics among women with PCOS undergoing myo-inositol, metformin, berberine, or a combination of metformin and berberine in standard clinical settings, and to investigate if disparities among treatment groups remained after controlling for initial characteristics. Materials and Methods: This retrospective observational cohort study included 148 women with PCOS diagnosed according to the Rotterdam criteria who completed six months of treatment with myo-inositol (n = 38), metformin (n = 52), berberine (n = 28), or combined metformin–berberine therapy (n = 30). Anthropometric, metabolic, lipid, and androgen parameters were assessed at baseline and after six months. Within-group changes were evaluated with correction for multiple testing using the Holm method. Given the non-random treatment allocation and baseline differences among groups, supplementary baseline-adjusted analyses were performed for the continuous outcomes. Results: Treatment groups differed significantly in several baseline metabolic variables including body mass index (BMI), fasting plasma glucose (FPG), fasting insulin and homeostatic model assessment of insulin resistance (HOMA-IR). After Holm correction for multiple testing, the metformin group showed significant reductions in BMI, FPG, markers of insulin resistance, lipid parameters, and androgen-related hormonal parameters, together with an increase in high-density lipoprotein cholesterol (HDL-C). In the myo-inositol group, significant reductions were observed in fasting insulin, HOMA-IR, total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, androstenedione, and dehydroepiandrosterone sulfate (DHEAS). In the berberine group, significant reductions were observed in BMI, fasting insulin, HOMA-IR, total cholesterol, triglycerides, and androstenedione. In the combined metformin–berberine group, significant reductions were observed in BMI, fasting insulin, HOMA-IR, total cholesterol, LDL-C, triglycerides, testosterone, androstenedione, DHEAS, and 17-hydroxyprogesterone, together with an increase in HDL-C. In the baseline-adjusted analyses, no significant overall treatment-group effects remained for the principal metabolic outcomes after correction for multiple testing, whereas significant overall treatment-group effects were observed for DHEAS and 17-hydroxyprogesterone. Conclusions: In this real-world observational cohort, six months of treatment with metformin, myo-inositol, berberine, or combined metformin–berberine therapy was associated with changes in several metabolic and hormonal parameters. However, substantial baseline differences among the clinically selected treatment groups and the absence of significant baseline-adjusted between-group effects for the principal metabolic outcomes preclude conclusions regarding comparative treatment efficacy. The observed between-group differences in selected hormonal outcomes warrant further investigation in prospective comparative studies.

Related

  1. Effect of a free sugar-restricted diet on anthropometric parameters, lipid profile, and glycemic control in women with polycystic ovary syndrome: a randomized controlled trial.
    Hajar Gholamshahi, Alireza Houshdar Tehrani, Danial Fotros +1
    BMC endocrine disordersPeer-reviewedCC BYFull textObstetrics, gynaecology & paediatricsEurope PMCPMC
  2. Aerobic and Aerobic-Oriented Exercise for Anthropometric, Androgen-Related, and Reproductive Endocrine Outcomes in Polyendocrine Metabolic Ovarian Syndrome (Polycystic Ovary Syndrome): A Systematic Review and Meta-Analysis
    Lanxin Qiu, Yunzhi Emma Huang, Mingnan Zhuang +2
    MetabolitesPeer-reviewedCC BY 4.0Full textObstetrics, gynaecology & paediatricsCrossrefEurope PMC
  3. The role of sitagliptin in modifying metabolic, hormonal and clinical parameters in polycystic ovarian syndrome patients: a randomized controlled trial
    Ahmed E. Altyar, Dina Y. Dessouky, Sara Abdallah Mohamed Salem +2
    Frontiers in pharmacologyPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC
  4. Redefining Gynecomastia Grading Using Anthropometric Parameters and Surgical Algorithm for Gynecomastia: A Single-center Study.
    Karthik Ramasamy, Mohammed Nishar Samiulla, Sushmita Vaidyanathan +4
    Plastic and reconstructive surgery. Global openPeer-reviewedCC BY-NC-NDFull textEpidemiology & public healthEurope PMC
  5. The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome.
    Andrijana Koceva, Andrej Janež, Mojca Jensterle
    Diabetes, metabolic syndrome and obesity : targets and therapyPeer-reviewedCC BY-NCFull textObstetrics, gynaecology & paediatricsEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{yanachkova2026comparative,
  title = {{Comparative Effects of Myo-Inositol, Metformin, Berberine, and Combination Therapy on Metabolic, Anthropometric and Hormonal Parameters in Women with Polycystic Ovary Syndrome: A 6-Month Observational Cohort Study}},
  author = {Vesselina Yanachkova and Angel Yordanov and Antonia Yaneva and Hristina Lebanova and Svetoslav Stoev},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  month = oct,
  doi = {10.3390/jcm15207765},
  url = {https://www.mdpi.com/2077-0383/15/20/7765},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Comparative Effects of Myo-Inositol, Metformin, Berberine, and Combination Therapy on Metabolic, Anthropometric and Hormonal Parameters in Women with Polycystic Ovary Syndrome: A 6-Month Observational Cohort Study
AU  - Vesselina Yanachkova
AU  - Angel Yordanov
AU  - Antonia Yaneva
AU  - Hristina Lebanova
AU  - Svetoslav Stoev
PY  - 2026
DA  - 2026/10/01
JO  - Journal of Clinical Medicine
DO  - 10.3390/jcm15207765
UR  - https://www.mdpi.com/2077-0383/15/20/7765
AB  - Background: Polycystic ovary syndrome (PCOS) is the most prevalent endocrine condition among women of reproductive age. It is marked by metabolic and reproductive irregularities and is often linked to insulin resistance, dyslipidemia, and obesity. Diverse methods of treatment are employed to enhance metabolic and hormonal parameters, including inositol-based supplements, metformin, and novel compounds such as berberine. Objective: To describe changes observed over six months in anthropometric, metabolic, lipid, and hormonal metrics among women with PCOS undergoing myo-inositol, metformin, berberine, or a combination of metformin and berberine in standard clinical settings, and to investigate if disparities among treatment groups remained after controlling for initial characteristics. Materials and Methods: This retrospective observational cohort study included 148 women with PCOS diagnosed according to the Rotterdam criteria who completed six months of treatment with myo-inositol (n = 38), metformin (n = 52), berberine (n = 28), or combined metformin–berberine therapy (n = 30). Anthropometric, metabolic, lipid, and androgen parameters were assessed at baseline and after six months. Within-group changes were evaluated with correction for multiple testing using the Holm method. Given the non-random treatment allocation and baseline differences among groups, supplementary baseline-adjusted analyses were performed for the continuous outcomes. Results: Treatment groups differed significantly in several baseline metabolic variables including body mass index (BMI), fasting plasma glucose (FPG), fasting insulin and homeostatic model assessment of insulin resistance (HOMA-IR). After Holm correction for multiple testing, the metformin group showed significant reductions in BMI, FPG, markers of insulin resistance, lipid parameters, and androgen-related hormonal parameters, together with an increase in high-density lipoprotein cholesterol (HDL-C). In the myo-inositol group, significant reductions were observed in fasting insulin, HOMA-IR, total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, androstenedione, and dehydroepiandrosterone sulfate (DHEAS). In the berberine group, significant reductions were observed in BMI, fasting insulin, HOMA-IR, total cholesterol, triglycerides, and androstenedione. In the combined metformin–berberine group, significant reductions were observed in BMI, fasting insulin, HOMA-IR, total cholesterol, LDL-C, triglycerides, testosterone, androstenedione, DHEAS, and 17-hydroxyprogesterone, together with an increase in HDL-C. In the baseline-adjusted analyses, no significant overall treatment-group effects remained for the principal metabolic outcomes after correction for multiple testing, whereas significant overall treatment-group effects were observed for DHEAS and 17-hydroxyprogesterone. Conclusions: In this real-world observational cohort, six months of treatment with metformin, myo-inositol, berberine, or combined metformin–berberine therapy was associated with changes in several metabolic and hormonal parameters. However, substantial baseline differences among the clinically selected treatment groups and the absence of significant baseline-adjusted between-group effects for the principal metabolic outcomes preclude conclusions regarding comparative treatment efficacy. The observed between-group differences in selected hormonal outcomes warrant further investigation in prospective comparative studies.
SN  - 2077-0383
ER  -